We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience.
- Authors
Broccoli, Alessandro; Argnani, Lisa; Morigi, Alice; Nanni, Laura; Casadei, Beatrice; Pellegrini, Cinzia; Stefoni, Vittorio; Zinzani, Pier Luigi
- Abstract
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refractory chronic lymphocytic leukemia (CLL), even in cases with unfavorable cytogenetics and molecular markers. All CLL patients' data treated at our Institute with ibrutinib have been retrospectively reviewed. Forty-six patients received ibrutinib either as frontline (10) or second or more advanced treatment (36). Five patients presented with TP53 mutations; 11 had the deletion of chromosome 17p; 17 displayed an unmutated immunoglobulin variable heavy chain status. The median number of cycles administered was 26. Among patients treated frontline, the best overall response rate (ORR) was 90.0%. In patients receiving ibrutinib as a second or later line ORR was 97.2%. Median progression-free survival was 28.8 and 21.1 months for patients treated frontline and as second/later line, respectively. Median overall survival was not reached for those treated frontline and resulted in 4.9 years for patients treated as second/later line. Grade 3–4 hematological toxicities were neutropenia, thrombocytopenia, and anemia. Grade 3–4 extrahematological toxicities included diarrhea, cutaneous rash, utero-vesical prolapse, vasculitis, and sepsis. Ibrutinib is effective and well tolerated in CLL. Responses obtained in a real-life setting are durable and the safety profile of the drug is favorable.
- Subjects
CHRONIC lymphocytic leukemia; IMMUNOGLOBULIN heavy chains; EXANTHEMA; RICHTER syndrome; PROGRESSION-free survival
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 24, p5845
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10245845